Skip to search formSkip to main contentSkip to account menu

GED0301

Known as: mongersen 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mongersen and SMAD-7 Inhibition, Not a Lucky 7 for Patients With IBD: When Trial Design Is as Important as Disease Therapy.
The phase II mongersen (GED-0301) trial produced unparalleled success rates in Crohn's disease and generated much hope for a… 
2017
2017
PD-008 A Study of Oral Mongersen (GED-0301) on Endoscopy and Clinical Activity (Stool Frequency and Abdominal Pain) in Crohn's Disease
Background: Mongersen (GED-0301) is an antisense oligodeoxynucleotide that is complementary to the sequence of the messenger RNA… 
2017
2017
Correlation of Clinical and Endoscopic Outcomes in Patients with Active Crohn’s Disease Treated with Mongersen (GED-0301)
2017
2017
PD-007 YI High-dose Infliximab Lowers 30-Day Colectomy Rates in Hospitalized Ulcerative Colitis Patients: A Propensity-Score Weighted Analysis
that maternal IBD affects both the offspring’s immediate and long-term morbidity, specifically congenital anomalies and… 
2016
2016
Editorial: mongersen in Crohn's disease – a new contribution to the beginning of a long‐awaited therapeutic revolution?
In a phase II trial assessing the efficacy and safety of mongersen, an oral SMAD7 anti-sense oligonucleotide for treating… 
2016
2016
PC.01.3 KNOCKDOWN OF SMAD7 WITH MONGERSEN ATTENUATES COLITIS AND COLITIS-DRIVEN FIBROSIS IN MICE
2015
2015
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
2015
2015
Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
2015
2015
Therapy: Oral SMAD7 antisense oligonucleotide proves effective for Crohn's disease
  • K. Ray
  • Nature Reviews Gastroenterology &Hepatology
  • 2015
  • Corpus ID: 6155421
2015
2015
Morbus Crohn – Patienten profitieren von Mongersen
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)